

# A novel *UNC93B1* gain-of-function mutation leads to TLR7 and TLR8 hyperactivation and systemic lupus erythematosus

Xu Han<sup>1,7</sup>, Ruoran Wang<sup>1,7</sup>, Seza Ozen<sup>2,7</sup>, Qintao Wang<sup>1,7</sup>, Wei Dong<sup>3,4</sup>, Yi Zeng<sup>1</sup>, Ouyuan Xu<sup>5</sup>,  
Seher Şener<sup>2</sup>, Li Guo<sup>6</sup>, Ying Gu<sup>4</sup>, Huanming Yang<sup>3,4</sup>, Xiaomin Yu<sup>1,\*</sup>, Panfeng Tao<sup>1,\*</sup>, Qing  
Zhou<sup>1,5,\*</sup>

1 Liangzhu Laboratory, Zhejiang University, and Department of Rheumatology, The Second  
Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

2 Department of Pediatrics, Division of Pediatric Rheumatology, Hacettepe University Faculty  
of Medicine, Ankara, Turkey

3 Hangzhou Institute of Medicine Chinese Academy of Sciences, Hangzhou, China

4 BGI, Shenzhen, China

5 Life Sciences Institute, Zhejiang University, Hangzhou, China

6 Department of Rheumatology Immunology & Allergy, Children's Hospital, National Clinical  
Research Center for Child Health, Zhejiang University School of Medicine, China

7 These authors contributed equally to this work

\* These authors jointly supervised this work: Qing Zhou, Panfeng Tao, Xiaomin Yu

e-mail: zhouqingnwu@gmail.com; taopanfang1109@gmail.com; yuxiaomin78@gmail.com

## Abstract

Dysfunctions in nucleic acid-sensing Toll-like receptors (TLRs) disrupt nucleic acid tolerance, leading to systemic lupus erythematosus (SLE). Here, we report a novel homozygous gain-of-function p.R95L mutation in the TLR chaperone protein *UNC93B1* in an SLE patient. Bulk and single-cell transcriptional analysis of the patient's peripheral blood mononuclear cells (PBMCs) revealed significantly elevated inflammation in T cells and myeloid cells due to enhanced dendritic cells function. The *UNC93B1* R95L mutation leads to hyperactivation of TLR7/8, but not TLR3/9, upon stimulation with specific agonists *in vitro*. Transgenic *Unc93b1*<sup>R95L/R95L</sup> mice develop inflammatory and autoimmune phenotypes, and the upregulation of inflammatory

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

30 signaling differs among organs, with a specific contribution of malfunctioned T cells and B  
31 cells. In human and mouse cell lines, the *UNC93B1* R95L mutation promotes TLR7/8 signaling  
32 by enhancing its binding to ssRNA, without affecting TLR7/8 translocation. Overall, our results  
33 elucidate the pathology of organs and the immunological profiles of immune cell populations  
34 in the development of SLE caused by the *UNC93B1* R95L mutation through the TLR7/8 axis.

## 36 Introduction

37 Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by  
38 autoantibodies targeting nuclear antigens and affecting multiple organ systems (1).  
39 Monogenic lupus refers to a group of diseases with lupus-like symptoms caused by mutations  
40 in single genes. These genes mainly affect complement pathways, type I interferon (IFN)  
41 signaling, nucleic acid sensing, RAS signaling pathways, and immune tolerance(2). Identifying  
42 these pathogenic genes is crucial for improving SLE classification and treatment. Genetic  
43 diagnosis enables personalized treatment, and understanding the mechanisms and effects of  
44 these mutations provides insights into SLE and other autoimmune diseases, aiding in the  
45 development of targeted therapies.

46  
47 Toll-like receptors (TLRs) are critical for recognizing microbial molecules and initiating immune  
48 responses. They consist of an extracellular domain for ligand recognition, a transmembrane  
49 domain, and a Toll-interleukin 1 receptor (TIR) domain for signaling. Upon ligand binding, the  
50 TIR domain dimerizes and recruits proteins to form the Myddosome complex, which activates  
51 pathways such as NF- $\kappa$ B and type I IFN(3).

52  
53 A subset of TLRs recognizes various forms of nucleic acids: TLR3 binds double-stranded RNA,  
54 TLR7 and TLR8 bind single-stranded RNA (ssRNA) fragments, and TLR9 binds CpG single-  
55 stranded DNA(4). TLR7, found in dendritic cells (DCs), monocytes, and B cells, recognizes  
56 ssRNA within endosomes(5, 6). Loss-of-function (LOF) mutations in *TLR7* cause  
57 immunodeficiency(7), while gain-of-function (GOF) mutations lead to abnormal activation of  
58 NF- $\kappa$ B and type I IFN pathways, resulting in SLE-like symptoms such as autoimmune

59 thrombocytopenia, elevated autoantibodies, complement deficiencies, arthritis, migraines,  
60 and kidney involvement(8-10). TLR8, expressed in myeloid DCs, monocytes, and  
61 neutrophils(11), also recognizes ssRNA in endosomes. GOF mutations in TLR8 cause  
62 immunodeficiency and inflammation(12). Patients show immunodeficiency symptoms like  
63 abnormal B cell differentiation, neutropenia, and infections, alongside inflammatory symptoms  
64 like arthritis, vasculitis, fever, T cell activation, increased cytokine production, and elevated  
65 NF-κB signaling. Tlr8 in mice is generally considered non-functional, and little is known about  
66 its regulation and role in autoimmune diseases.

67  
68 UNC93B1 is a chaperone protein crucial for transporting TLR3, TLR7, TLR8, and TLR9 from  
69 the endoplasmic reticulum (ER) to endosomes where these receptors initiate signaling(13, 14).  
70 Mice with homozygous *Unc93b1*<sup>H412R</sup> mutation are more susceptible to pathogens due to  
71 impaired binding of Unc93b1 to TLR3, TLR7, and TLR9, trapping them in the ER and blocking  
72 signal transduction(15). Patients with *UNC93B1* LOF mutations are prone to herpes simplex  
73 encephalitis due to dysfunctional endosomal TLRs, with reduced responses of immune cells  
74 to TLR agonists(16). Understanding the role of UNC93B1 in TLR regulation is critical for  
75 elucidating its involvement in autoimmune diseases like SLE. Recent structures have  
76 identified potential key regions involved in UNC93B1-TLR7 interactions(17), but the  
77 significance of these residues in UNC93B1 and TLR7 function remains unexplored.

78  
79 Here, we identify a patient with early-onset SLE carrying homozygous *UNC93B1* R95L  
80 mutation. Through a series of experiments in human and mouse model, we elucidate the  
81 pathology of organs and the immunological profiles of immune cell populations in the  
82 development of SLE caused by the *UNC93B1* R95L mutation through the TLR7/8 axis.

83

## 84 **Results**

### 85 **A novel *UNC93B1* pathogenic mutation in a patient with early-onset SLE**

86 The proband is a female who presented with symptoms suggesting early-onset SLE. These  
87 symptoms included fevers, fatigue, discoid and maculopapular rashes, and

88 photosensitivity (**Figure 1A**). Immunologic studies revealed positive anti-nuclear antibody  
89 (ANA), anti-double-stranded DNA (anti-dsDNA) antibodies exceeding 800 U/L, as well as  
90 positive anti-Smith (anti-Sm) and anti-Ribonucleoprotein (anti-RNP) antibodies. The patient  
91 had hypocomplementemia with reduced levels of C3 (0.33 g/L, normal range 0.8-1.6 g/L) and  
92 C4 (0.05 g/L, normal range 0.15-0.4 g/L). C-reactive protein (CRP) level was normal, her  
93 erythrocyte sedimentation rate (ESR) was elevated, ranging between 40-60 mm/hour (normal  
94 range 1-10 mm/hour). Based on the 2019 EULAR/ACR criteria(18), she was diagnosed with  
95 early-onset SLE. Currently she is on prednisolone at a dosage of 5 mg/day,  
96 hydroxychloroquine at 150 mg/day, and mycophenolate mofetil at 750 mg/day.

97  
98 Whole-exome sequencing of the proband and her parents identified a homozygous mutation  
99 in *UNC93B1*: NM\_030930:c.284G>T, p.Arg95Leu (R95L) (**Figure 1, B and C**). Her healthy  
100 parents were heterozygous carriers of this variant. The R95 residue is highly conserved across  
101 species (**Figure 1D**). This mutation was not found as homozygous in public databases,  
102 including gnomAD v4, Kaviar, and chinaMap. *In silico* modeling predicted that this mutation  
103 impacts protein function, with a CADD score of 35 and a GERP score of 4.55, both indicating  
104 a deleterious effect.

105

### 106 **Activation of inflammatory signaling in the patient**

107 We obtained serum samples from the patient and quantified cytokines using cytometric bead  
108 array (CBA) and enzyme-linked immunosorbent assay (ELISA). The analysis revealed  
109 markedly increased production of proinflammatory cytokines IL-6 and IFN- $\alpha$ , chemokine IP-  
110 10, and macrophage colony-stimulating factors (M-CSF) and Granulocyte-CSF (G-CSF)  
111 compared to healthy controls (**Figure 1, E and F**).

112

113 To examine the transcriptional differences between the patient and healthy controls, we  
114 performed bulk RNA sequencing on peripheral blood mononuclear cells (PBMCs) samples.  
115 Differential gene expression analysis showed that expression of inflammatory response genes  
116 was elevated in patient compared to healthy controls (**Supplemental Figure 1A**). Gene set

117 enrichment analysis (GSEA) showed that type I IFN and NF- $\kappa$ B signaling were top-ranked  
118 among the upregulated pathways in the patient (**Supplemental Figure 1B**). The heightened  
119 expression of genes in type I IFN and NF- $\kappa$ B pathways were also observed in patient (**Figure**  
120 **1G, Supplemental Figure 1A**). These results suggested specific effect of these two pathways  
121 in the patient's inflammatory manifestation. The changes in the type I IFN pathway genes were  
122 notably pronounced. Quantitative PCR (qPCR) confirmed increased transcription of type I IFN,  
123 including *IFNA2* and *IFNB1*, type I IFN-stimulated gene (ISG) *IFI44*, as well as *IL6*, which is  
124 regulated by the NF- $\kappa$ B pathway, in the patient compared to healthy controls (**Figure 1H**).  
125 Many SLE patients exhibit elevated levels of type I IFN, which correlates with the secretion of  
126 autoantibodies, disease severity, and heterogeneity(19). Thus, the abnormal activation of the  
127 type I IFN signaling pathway may be a critical factor contributing to the patient's SLE.

128  
129 To further identify specific cell populations and immunological pathways involved in the  
130 patient's pathology, we analyzed the single-cell transcriptomes of PBMCs from the patient and  
131 three healthy controls. Based on the integration and unsupervised clustering of single-cell  
132 sequencing data, we identified 18 cell populations according to specific profiles of marker gene  
133 expression (**Figure 1I, Supplementary Figure 1C**). Compared to healthy controls, patient's  
134 PBMCs showed elevated signal in NF- $\kappa$ B and type I IFN pathways (**Figure 1J**). Differential  
135 expression analysis displayed a distinct expression pattern of key genes in NF- $\kappa$ B pathway,  
136 such as *RELA*, *TNFAIP3* in myeloid cells and T cells, and critical genes in type I IFN pathway,  
137 including *ISG15*, *IFI44L* in most immune cells (**Figure 1K**). Among myeloid cells, plasmacytoid  
138 DCs (pDCs) are the primary interferon-producing cells(20), whereas monocyte-derived DCs  
139 (moDCs) and conventional DCs (mDCs) could activate T cells through antigen presentation(21,  
140 22). Enrichment of IL-17 and type I IFN signaling in DCs and T cells implicated specific  
141 contributions of DCs subsets, pDCs, mDCs, and moDCs, to the patient's manifestation  
142 through T cell activation and type I IFN production (**Figure 1L, Supplemental Figure 1D**).

143  
144 These results demonstrated dysregulated inflammatory regulation in the patient, suggesting  
145 that *UNC93B1* R95L mutation plays a driving role in the activation of immune cell responses.

146

147 ***UNC93B1* R95L mutation promotes inflammation through TLR7/TLR8 activation**

148 Unrestrained intracellular TLR activation can lead to responses to self-nucleic acids and  
149 autoimmunity(8). To investigate the effect of the *UNC93B1* R95L mutation on intracellular  
150 TLRs (TLR3, TLR7, TLR8, TLR9), we co-expressed wild-type *UNC93B1*, *UNC93B1* R95L  
151 mutant, and *UNC93B1* H412R mutant (negative control) with different TLRs in HEK293T cells.  
152 We measured the NF- $\kappa$ B reporter activity and/or the levels of IL-8 transcription following  
153 stimulation with specific TLR agonists (TLR3: Poly(I:C); TLR7/TLR8: R848; TLR9: ODN2216).  
154 These assays revealed that the *UNC93B1* R95L mutation enhanced the activation of TLR7,  
155 TLR8, and TLR9, but not TLR3 (**Figure 2, A-D**).

156

157 In the human monocytic cell line THP-1, the *UNC93B1* R95L mutant enhanced activation by  
158 the TLR7/8 dual agonist R848 and the TLR8-specific agonist TLR8-506, while there was no  
159 significant effect on TLR3 and TLR4, which are *UNC93B1*-independent (**Figure 2E**). In mouse  
160 macrophage cell line RAW 264.7 (where TLR8 is non-functional), the *UNC93B1* R95L mutant  
161 increased TLR7 activation upon R848 stimulation, significantly elevating the transcription  
162 levels of NF- $\kappa$ B downstream genes such as *Tnf* and *Il1b* (**Supplemental Figure 2A**).  
163 Intracellular cytokine staining of *Tnf* further confirmed that the *UNC93B1* R95L mutant  
164 enhanced TLR7 activation by various TLR7 agonists (**Figure 2F**). Both chloroquine, which  
165 inhibits TLR activation by altering endosomal pH and inhibiting the ectodomain cleavage, and  
166 M5049, a small molecule inhibitor of TLR7/8, effectively suppressed R95L-induced TLR7  
167 activation and its downstream signaling (**Figure 2G**).

168

169 Bone marrow-derived dendritic cells (BMDCs) and macrophages (BMDMs) from the  
170 homozygous *Unc93b1*<sup>R95L</sup> mice showed enhanced activation of NF- $\kappa$ B and type I IFN  
171 signalings in response to TLR7 ligands but not ligands of TLR3, TLR4, and TLR9 (**Figure 2,**  
172 **H and I, Supplemental Figure 2B**). Interestingly, in BMDCs, the transcription levels of both  
173 NF- $\kappa$ B and type I IFN-related genes were significantly upregulated, whereas in BMDMs, type  
174 I IFN-related gene expression showed no significant changes.

175

176 Collectively, experiments across human cell lines, mouse cell lines, and primary isolated  
177 mouse cells demonstrate that the *UNC93B1* R95L mutation confers a gain-of-function effect  
178 with selectively enhanced TLR7/8 but not TLR3/9 activation, leading to downstream NF-κB  
179 and type I IFN signaling dysregulation.

180

### 181 **Mice with *Unc93b1*<sup>R95L</sup> mutation develop systemic inflammation and autoimmune** 182 **pathology**

183 To verify that the *UNC93B1* R95L mutation drives autoimmune manifestation and abnormal  
184 inflammatory signaling, we generated *Unc93b1*<sup>R95L/R95L</sup> knock-in mice on a C57BL/6J  
185 background using CRISPR/Cas9 technology (**Figure 3A**). We monitored mice body weight  
186 and cutaneous manifestation weekly, and measured plasma anti-dsDNA antibody level  
187 biweekly from postnatal day 21 until the phenotype stabilized. Over a 9-week period, no  
188 significant difference in body weight was observed between mutant and control mice,  
189 regardless of sex (**Figure 3B**). Tissue analysis revealed that *Unc93b1*<sup>R95L/R95L</sup> mice exhibited  
190 significant splenomegaly and slight hepatomegaly compared to controls, whereas  
191 *Unc93b1*<sup>+ /R95L</sup> mice showed no differences (**Figure 3C, Supplemental Figure 3A**). Elevated  
192 levels of autoantibodies (including dsDNA, dsRNA, and ANA), C-reactive protein, and C3 were  
193 observed in *Unc93b1*<sup>R95L/R95L</sup> mice compared to *Unc93b1*<sup>+ /+</sup> controls, as measured by ELISA  
194 (**Figure 3D**). Given the weaker phenotype observed in males, we focused subsequent  
195 inflammation analysis on female mice. Plasma cytokines and chemokines analysis revealed  
196 elevated levels of pro-inflammatory cytokines Il-6 and Il-1β, as well as the chemokine Cxcl1,  
197 in *Unc93b1*<sup>R95L/R95L</sup> mice compared to *Unc93b1*<sup>+ /+</sup> controls (**Figure 3E**). These data indicate  
198 that the *Unc93b1*<sup>R95L</sup> mutation leads to autoimmune and inflammatory phenotypes in mice,  
199 recapitulating the clinical symptoms of the patient.

200

201 To further investigate the pathological mechanisms underlying the autoimmune and  
202 inflammatory symptoms in *Unc93b1*<sup>R95L/R95L</sup> mice, we analyzed the pathological differences in  
203 the spleen, kidney, lung, liver, brain, quadriceps, and plasma, comparing *Unc93b1*<sup>R95L/R95L</sup>

204 mice with littermate controls.

205

206 Histological examination using hematoxylin and eosin (H&E) staining revealed significantly  
207 increased number of splenocytes and enlarged white pulp areas in the spleens of both  
208 *Unc93b1<sup>+ / R95L</sup>* and *Unc93b1<sup>R95L / R95L</sup>* mice, with indistinct boundaries between the white and  
209 red pulp (**Figure 3F**). Periodic acid-Schiff (PAS) staining of kidneys showed significantly  
210 increased glomerulus areas in both *Unc93b1<sup>+ / R95L</sup>* and *Unc93b1<sup>R95L / R95L</sup>* mice, with  
211 inflammatory cell infiltration in the renal interstitial area, particularly around renal tubules in  
212 *Unc93b1<sup>R95L / R95L</sup>* mice (**Figure 3G**). This was accompanied by glomerular damage  
213 characterized by increased cell numbers, immune complex deposition, and expansion of  
214 mesangial matrix (**Supplemental Figure 3B**). Lung tissue analysis showed reduced alveolar  
215 spaces and thickened septa in both *Unc93b1<sup>+ / R95L</sup>* and *Unc93b1<sup>R95L / R95L</sup>* mice, with pulmonary  
216 congestion noted in *Unc93b1<sup>R95L / R95L</sup>* mice. The liver of *Unc93b1<sup>R95L / R95L</sup>* mice exhibited  
217 prominent glycogen storage within hepatocytes and marked inflammatory cell infiltration  
218 (**Figure 3H**). These observations were consistent with significant hypoglycemia in  
219 *Unc93b1<sup>R95L / R95L</sup>* mice (**Figure 3I**). GSEA further revealed an upregulation of inflammatory  
220 signaling and downregulation of glycogen metabolism downstream signaling in  
221 *Unc93b1<sup>R95L / R95L</sup>* mice liver (**Figure 3J**). Immunofluorescence staining of glomeruli revealed  
222 elevated IgG and C3 deposition in *Unc93b1<sup>R95L / R95L</sup>* mice, while *Unc93b1<sup>+ / R95L</sup>* mice showed a  
223 slight increase in IgG deposition (**Figure 3K**). These findings, aligned with PAS staining results,  
224 confirm immune complex deposition and highlight the autoimmune pathology in  
225 *Unc93b1<sup>R95L / R95L</sup>* mice.

226

227 These analyses suggest that the *Unc93b1<sup>R95L</sup>* mutation leads to widespread tissue  
228 inflammation and immune cell infiltration in multiple organs.

229

### 230 **Differential activation of NF- $\kappa$ B and type I IFN pathways in various tissues**

231 In the patient's PBMCs, we observed a more ubiquitous upregulation of genes in type I IFN  
232 pathway compared to NF- $\kappa$ B pathway, implying differential activation patterns of these



233 pathways through the dysfunctional UNC93B1/TLR axis in various tissues. To investigate the  
234 effects of the *UNC93B1* R95L mutation on inflammatory pathways in different tissues, we  
235 performed qPCR to measure the transcription levels of downstream genes in various tissues  
236 of the mice.

237

238 Interestingly, the *Unc93b1*<sup>R95L</sup> mutation significantly enhanced the activation of NF-κB pathway  
239 in the spleen and liver (**Figure 3L, Supplemental Figure 3C**). Additionally, upregulated genes  
240 in splenocytes from *Unc93b1*<sup>R95L/R95L</sup> mice exhibited enrichment in inflammatory and  
241 autoimmune signaling pathways, implicating a specific contribution of splenocytes to immune  
242 dysregulation (**Supplemental Figure 3D**). In contrast, the mutation significantly enhanced the  
243 activation of the type I IFN pathway in the kidney and brain (**Figure 3L**). Despite the  
244 morphological evidence of substantial lung tissue damage, qPCR results indicated that both  
245 the NF-κB and type I IFN pathways were less pronounced in the lungs compared to other  
246 tissues. The quadriceps muscle served as a negative control with no differential expression of  
247 genes related to either pathway (**Supplemental Figure 3E**).

248

249 These findings suggest that the *Unc93b1*<sup>R95L</sup> mutation differentially affects NF-κB and type I  
250 IFN signaling pathways across various tissues, contributing to the complex autoimmune and  
251 inflammatory phenotype observed in these mice.

252

### 253 **Effects of *Unc93b1*<sup>R95L</sup> mutation on immune cell populations in mice**

254 Since the *Unc93b1*<sup>R95L</sup> mutation affected inflammatory signaling in various tissues, we next  
255 explored the impact of *Unc93b1*<sup>R95L</sup> mutation on exact immune cell populations to elaborate  
256 on its pathogenesis to SLE. We performed single-cell sequencing on murine spleen tissue  
257 from *Unc93b1*<sup>R95L/R95L</sup> and *Unc93b1*<sup>+/+</sup> mice. Unsupervised clustering identified 28 cell  
258 populations from murine splenocytes (**Figure 4A, Supplemental Figure 4A**). In view of  
259 globally activated inflammatory response and autoimmune manifestation in the spleen of  
260 *Unc93b1*<sup>R95L/R95L</sup> mice, we carried out differential expression analysis among cell populations  
261 between *Unc93b1*<sup>R95L/R95L</sup> and *Unc93b1*<sup>+/+</sup> mice. Amplified signaling in NF-κB pathway was

262 observed in myeloid cells and T cells from *Unc93b1*<sup>R95L/R95L</sup> mice, with significant activation of  
263 NF-κB through pathways like TNF signaling, which suggests that *Unc93b1*<sup>R95L</sup> mutation drives  
264 systemic inflammation state through T cells (**Figure 4B**). Additionally, we also detected  
265 escalated production of immunoglobulin in B cells and plasma cells in *Unc93b1*<sup>R95L/R95L</sup> mice,  
266 with ascendant gene expression in the gene set about SLE pathogenesis, which implicated a  
267 promoting role of the *Unc93b1*<sup>R95L</sup> mutation in autoimmune pathology through B cells (**Figure**  
268 **4C**). These results implicated a dysfunctional state of lymphocytes in *Unc93b1*<sup>R95L/R95L</sup> mice,  
269 which may contribute to the SLE pathogenesis.

270

271 To further investigate specific alterations of immune cells caused by the *Unc93b1*<sup>R95L</sup> mutation,  
272 we analyzed the immune phenotype in the spleen and peripheral blood of *Unc93b1*<sup>+/+</sup> and  
273 *Unc93b1*<sup>R95L/R95L</sup> mice. Single-cell analysis of splenocytes revealed an increase of Treg cells,  
274 follicular helper T (Tfh) cells, and plasma cells and a reduction of CD4<sup>+</sup> T cells, naive CD8<sup>+</sup> T  
275 cells in the *Unc93b1*<sup>R95L/R95L</sup> mice (**Supplemental Figure 4B**). Flow cytometry further  
276 confirmed a disruption in lymphocyte composition, with an increase in germinal center (GC) B  
277 cells, age-associated B cells (ABCs), follicular B cells, and plasma cells, indicating continuous  
278 activation of B cells in the spleens of *Unc93b1*<sup>R95L/R95L</sup> mice (**Figure 4, D-G, Supplemental**  
279 **Figure 5, A-C**), consistent with the high levels of autoantibodies found in the plasma of these  
280 mice.

281

282 The number of Naive T cells were reduced, whereas effector memory T cells have increased,  
283 suggesting a shift towards an activated or memory state, indicative of ongoing immune  
284 activation and chronic inflammation characteristics of SLE (**Figure 4, H and I, Supplemental**  
285 **Figure 5, D and E**). Additionally, expansions in NKT cells, double-negative T (DNT) cells, Treg  
286 cells, effector Th (eTh) cells, and Th17 cells indicated the presence of inflammation and  
287 autoimmune responses in *Unc93b1*<sup>R95L/R95L</sup> mice. The rise in follicular helper T (Tfh) cells  
288 aligns with the expansion in GC B cells, reflecting an active autoimmune response (**Figure 4J,**  
289 **Supplemental Figure 5F**).

290

291 A reduction in NK cells, a cell type often impaired in SLE, suggests a dysfunction in immune  
292 regulation. An increase in pDCs number can lead to excess production of interferon, promoting  
293 inflammation and autoimmune responses in SLE. The decrease in mDCs, critical for antigen  
294 presentation and T cell activation, could be linked to abnormal antigen presentation  
295 dysfunctions and immune dysregulation. An expansion in Ly6C-high monocytes is associated  
296 with inflammation and tissue damage responses (**Figure 4K, Supplemental Figure 5G**). We  
297 also observed a further concentrated MHC-II signaling and upregulation of ICAM signaling  
298 from DCs to T cells (**Supplemental Figure 5, H and I**) in *Unc93b1<sup>R95L/R95L</sup>* mice splenocytes  
299 in single-cell analysis.

300

301 Collectively, these findings illustrate the altered immune landscape caused by the *UNC93B1*  
302 R95L mutation, highlighting its role in promoting systemic inflammation and autoimmunity.

303

### 304 **UNC93B1 R95L mutation enhances ligand binding to TLR7 by weakening the interaction** 305 **between UNC93B1 and TLR7**

306 We next examined how the *UNC93B1* R95L mutation affects TLR7 and TLR8 activation. The  
307 structure of the TLR7-*UNC93B1* complex reveals that the *UNC93B1* R95L mutation is located  
308 within the H1 helix (residues 91-97) between the TM1 and TM2 transmembrane domains of  
309 *UNC93B1* (**Figure 5A**). This region directly interacts with two loop regions of the C-terminal  
310 LRR-CT domain of TLR7 and exhibits strong shape complementarity(17). In HEK293T cells,  
311 immunoprecipitation and western blotting results indicated that the *UNC93B1* R95L mutation  
312 significantly weakened the interaction between *UNC93B1* and both TLR7 and TLR8 (**Figure**  
313 **5, B and C**). We further investigated the interactions between *UNC93B1* and endogenous  
314 TLR7. We generated RAW 264.7 cell lines stably expressing *UNC93B1* (WT)-BirA\* and  
315 *UNC93B1* (R95L)-BirA\* and performed streptavidin pull-down. Western blotting results  
316 showed that the *UNC93B1* R95L mutation reduced the association between *UNC93B1* and  
317 cleaved forms of TLR7 (**Figure 5D**).

318

319 The weakened interaction did not alter TLR7 trafficking into endosomes, as receptor cleavage,

320 which occurs within endosomes, was unaffected (**Figure 5D**). We also isolated endosomes  
321 and lysosomes (late endosomes) from RAW 264.7 cells. Western blot analysis showed  
322 comparable levels of TLR7 in both wild-type and UNC93B1 R95L mutant cells (**Figure 5E**).  
323 Immunofluorescence microscopy revealed normal colocalization of TLR7 with Eea1 and  
324 Lamp1 in mouse BMDMs (**Figure 5, F and G**). These findings indicate that the UNC93B1  
325 R95L mutation does not impact the trafficking of TLR7 from the ER to endosomes or from  
326 endosomes to lysosomes, suggesting a trafficking-independent role for UNC93B1.

327

328 The weakened interaction between UNC93B1 and TLR7 might alter the receptor conformation  
329 and increase the affinity for ligand binding, thereby activating the inflammatory pathway. To  
330 explore this, we conducted RNA pull-down experiments using mouse BMDCs. The results  
331 revealed that the UNC93B1 R95L significantly enhanced the binding of TLR7 to ssRNA  
332 (**Figure 5H**).

333

### 334 **Discussion**

335 Our study characterized a novel homozygous gain-of-function mutation p.R95L in *UNC93B1*  
336 leading to early-onset SLE. We also delineate distinct altered inflammatory responses amidst  
337 organs and immune cell populations during the SLE development caused by the *UNC93B1*  
338 R95L mutation. Limited by the heterogeneity of SLE, preventing SLE patients from sequelae  
339 during SLE progression is challenging. Our work enriched the spectrum of SLE pathogenic  
340 mutations, which could ameliorate the prognosis and disease development of SLE-like  
341 patients through early diagnosis and intervention.

342

343 *UNC93B1* deficiency was firstly reported in 2006 with immunodeficiency and infections(16).  
344 Recently, a series of *UNC93B1* gain-of-function mutations were reported as pathogenic,  
345 predisposing to early-onset SLE and arthritis(23-27). These *UNC93B1* gain-of-function  
346 mutations exhibit dominant and recessive inheritance, however, some mutations are not rare  
347 variants in public database like gnomAD, which is unusual for monogenic disorders caused  
348 by gain-of-function mutations. Besides, some mutations, such as T93I, R336C, and V117L,

349 show dosage effects in phenotype presentation in both patients and animal models to different  
350 extents. In our study, the *UNC93B1* R95L mutation also displays additive effects on  
351 autoimmune pathology and inflammatory response in different tissues. Though parents of  
352 patients with *UNC93B1* gain-of-function mutations (R95L, E92G, I317M) have not presented  
353 with SLE manifestation, current results suggest that gain-of-function *UNC93B1* mutations, no  
354 matter mono-allelic or bi-allelic, have potential for SLE development. The variable expressivity  
355 and penetrance in the SLE caused by *UNC93B1* gain-of-function mutations implicate a veiled  
356 function of *UNC93B1* in the innate immune, encouraging further investigation into the  
357 mechanism of *UNC93B1* in SLE pathogenesis beyond the regulation of TLR signaling.

358

359 As unrestricted intracellular nucleic-acid sensing leads to autoimmune or inflammatory  
360 diseases(28-31), activation of intracellular TLRs is restrained within cells. TLR7 must be  
361 transported to the endosome, where it is cleaved by proteases in the Z-loop region for  
362 dimerization. TLR7 has two substrate-binding sites that recognize different substrates. The  
363 sequential binding of these substrates induces conformational changes in TLR7, leading to  
364 the close dimerization of the C-terminal TIR domain and initiating signal cascades.  
365 Subsequently, activated TLR7 is sorted into multivesicular bodies (MVBs) and late lysosomes  
366 for degradation, terminating the signal.

367

368 *UNC93B1* is involved not only in the transport of TLRs to endosomes but also in orchestrating  
369 their functions. The D34A mutation in N-terminal domain of *UNC93B1* can enhance the  
370 response of TLR7 while inhibiting the response of TLR9, leading to systemic lethal  
371 inflammation in mice(32). The C-terminal end of *UNC93B1* interacts with syntenin-1 to  
372 transport TLR7 to the phagosome, thereby terminating TLR7 activation. A mutation in the C-  
373 terminal region (PKP530-532) weakens this interaction with syntenin-1, promoting TLR7  
374 activation and resulting in lupus-like symptoms in mice(33). Additionally, studies have shown  
375 that the interaction between *UNC93B1* and TLR9 in endosomes affects TLR9's ligand binding  
376 and activation. The S282A point mutation disrupts the dissociation of *UNC93B1* from TLR9 in  
377 endosomes, thereby impairing TLR9 signaling pathway activation in mouse macrophages and

378 dendritic cells(34).

379

380 In our study, both humans and mice carrying the *UNC93B1* R95L homozygous mutation  
381 exhibited autoimmune and systemic inflammatory phenotypes. Based on our mechanistic  
382 research and existing structural studies, we propose the following model (**Figure 5I**): in the  
383 absence of ligand binding, TLR7 or TLR8 exists as a pre-dimer with the C-terminal TIR  
384 domains far apart and the N-terminal domains unfavorable for ligand binding. Upon ligand  
385 binding at the first binding site, the LRR domain undergoes a conformational change that  
386 promotes binding at the second site, further driving conformational changes that lead to the  
387 aggregation of the C-terminal TIR domains and the initiation of downstream signaling  
388 pathways. The two-turn helix H1 (residues 91-97) formed between the TM1 and TM2  
389 transmembrane domains of *UNC93B1* directly contacts two loop regions of the TLR7 C-  
390 terminal LRR-CT domain, thus restricting TLR7 conformational changes and setting the  
391 activation threshold of potentially self-reactive TLR7. The *UNC93B1* R95L mutation weakens  
392 the interaction between *UNC93B1* and TLR7, enhancing the binding of the LRR domain to the  
393 ligand and activating downstream signaling pathways. Recent studies reported that the E92G  
394 and T93I mutations also weaken the interaction between *UNC93B1* and TLR7, leading to  
395 TLR7 hyperactivation, likely through a similar mechanism.

396

397 Gain-of-function *UNC93B1* mutations affecting innate immune through TLR7/8 but not other  
398 endogenous TLRs have been well established in recent research. Our results support this  
399 selective activation of TLRs in mutant *UNC93B1*-mediated inflammation. The interface  
400 between *UNC93B1* and TLR3 or TLR7 shows no differences, while the crystal structures of  
401 TLR7/8 display their distinct oligomerization states in ligand recognition(17, 35), implicating a  
402 different mechanism in TLR signaling activation. TLR7 and TLR8 exist as pre-dimers even in  
403 the absence of ligand binding, with the regulation of antagonizing binding of *UNC93B1* (in a  
404 2:2 pattern) changing the conformation from inactive to active forms. In contrast, TLR3 and  
405 TLR9 are monomers that interact with *UNC93B1* in a 1:1 pattern without ligand binding. Upon  
406 stimulation, *UNC93B1* dissociates, allowing the formation of active dimers. This may partially

407 explain why the UNC93B1 R95L mutation specifically promotes the activation of TLR7 and  
408 TLR8, but has no effect on the activation of TLR3 and TLR9. These findings indicate the  
409 diverse function of UNC93B1 in intracellular nucleic acid homeostasis, suggesting the  
410 importance of future research on the dynamic balance of endosomal TLRs during SLE  
411 development resulting from activated UNC93B1.

412  
413 In our results, the *UNC93B1* R95L mutation disrupts the interaction between UNC93B1 and  
414 TLR7 as the previously characterized UNC93B1 H412R mutation does, however, UNC93B1  
415 R95L still promotes TLR7/8 signaling. It was reported that the exogenous antigen processing  
416 is abolished in *UNC93B1<sup>H412R</sup>* mice(13). Based on the expression pattern of UNC93B1 in  
417 protein atlas database, UNC93B1 is absent in T cells. Nevertheless, in our results, T cells from  
418 the patient and animal model with the UNC93B1 R95L mutation display activated state in the  
419 development of SLE through activation from DCs. Besides, we also observed specific  
420 enrichment of immunoglobulin production and SLE signaling in B cells from *Unc93b1<sup>R95L/R95L</sup>*  
421 mice. Our results emphasize the importance of antigen presentation and humoral immunity in  
422 the immune dysregulation mediated by *UNC93B1* gain-of-function mutations.

423  
424 To treat SLE caused by TLR7/8 hyperactivation due to UNC93B1 mutations, several  
425 approaches may be considered. JAK inhibitors can block the JAK-STAT signaling pathway,  
426 reducing inflammation and immune responses driven by cytokines such as IFN- $\alpha$ , which are  
427 upregulated by TLR7/8 activation. Hydroxychloroquine (HCQ) inhibits endosomal acidification,  
428 thus blocking TLR7/8 activation, and is already widely used in SLE treatment with a good  
429 safety profile. Additionally, inhibitors targeting TLR7/8, MyD88, and IRAK1/4 can block the  
430 TLR7 signaling pathway with better precision, reducing inflammation with fewer potential off-  
431 target effects. These inhibitors, though promising, are still largely undergoing clinical trials and  
432 require further evaluation for long-term safety and efficacy.

433

## 434 **Methods**

### 435 **Sex as a biological variable**

436 Our study examined male and female mice, and sex-dimorphic effects are reported. The sex  
437 of human involved in this study was not considered as a biological variable.

438

#### 439 **Mice**

440 *Unc93b1* R95L point mutation mice were generated in a C57BL/6J background using  
441 CRISPR-Cas9-mediated gene editing technology. Genomic sequence  
442 (ENSMUST00000162708.7) was obtained from Ensembl (<https://ensembl.org/>) and  
443 compared to human genes to ascertain sequence conservation. The sgRNA used was 5'-  
444 GCCATACTTCACCTCTCTGT-AGG-3'. The donor single-stranded oligonucleotide was: 5'-  
445 CAGCCTTGCCGTGAGCTTGTTTAGTTGTTCTGAGCCAGACTGATTAGAGCTCTCTACGA  
446 TGCTCCCTGTCCCCAGGCCTCCTGCAGATGCAACTGATCCTGCACTATGATGAGACCT  
447 ACCTCGAGGTGAAGTATGGCAACATGGGGCTGCCGGACATCGATAGCAAGATGCTGAT  
448 GGGTATCAACGTGACGCCTATCGCTGCCCTGCTCTACACACCTGTGCTCATCAGGTGC  
449 CAACTTC-3'. The primers designed to amplify the region including the R95L mutation are  
450 as follows: Forward, 5'-CTGGGAACGGGAGTCTTGT-3'; Reverse, 5'-  
451 AACAAAGCAAGGCCTCTCTGC-3'.

452

453 Both male and female mice were used and their genders are indicated in the figures or figure  
454 legends. Within genotypes, mice were randomly allocated in all experiments. Data collection  
455 and analysis were not performed blind to the conditions of the experiments, except for  
456 histopathology. No animals or data points were excluded except contaminated samples.

457

#### 458 **Whole exome sequencing and Sanger sequencing**

459 Genomic DNA from the patient and family members were isolated from peripheral blood using  
460 Maxwell RSC Whole Blood DNA Kit (Promega, AS1520). Whole exome sequencing (WES)  
461 and data analysis were performed as previously described(36, 37). ANNOVAR (2019Oct24)  
462 was used to annotate variants. Variants that appeared in gnomAD, Kaviar, dbSNP, and an in-  
463 house database were filtered out. Variants were further filtered by homozygous inheritance.  
464 Sanger sequencing was used to confirm the *UNC93B1* variant identified by WES.



465

## 466 **Cell preparation, culture, and stimulation**

467 RAW 264.7, THP-1 and HEK293T cell lines were obtained from the American Type Culture  
468 Collection. All cell lines tested negative for Mycoplasma contamination. PBMCs were  
469 separated by Lymphocyte Separation Medium (MP, 50494) according to the manufacturer's  
470 instructions. BMDMs were differentiated for 6-8 days in complete medium containing 50 ng/mL  
471 M-CSF (PeproTech, 315-02). BMDCs were differentiated for 7 days in complete medium  
472 containing 20 ng/mL GM-CSF (PeproTech, 315-03). For UNC93B1 overexpressing stable cell  
473 lines, a coding sequence expressing UNC93B1 and BirA\* biotin ligase fusion protein  
474 (UNC93B1-BirA\*) was cloned into the retroviral MSCV-puro vector. THP-1 and RAW 264.7  
475 cells were transduced with retroviruses expressing UNC93B1-BirA\* and subjected to  
476 puromycin selection.

477

478 RAW 264.7, HEK293T and BMDMs were grown in Dulbecco's Modified Eagle Medium (DMEM,  
479 Gibco) supplemented with 10% FBS (Noverse) and penicillin/streptomycin (Gibco). THP-1,  
480 PBMCs and BMDCs were grown in RPMI-1640 (Gibco) supplemented with 10% FBS and  
481 penicillin/streptomycin.

482

483 R848 (Resiquimod, Sigmaaldrich, SML0196), a dual TLR7 and TLR8 synthetic agonist was  
484 used to stimulate HEK293T (5 µg/mL), RAW 264.7 (25 ng/mL, 100 ng/mL), BMDCs (25 ng/mL),  
485 and THP-1 (100 ng/mL) for the indicated amount of time. ssRNA40 (InvivoGen, tlr-lrna40),  
486 the natural ligand of the TLR7 and TLR8 was used to stimulate BMDCs (0.1 µM, 1 µM),  
487 BMDMs (1 µM) for the indicated amount of time. CL307 (InvivoGen, tlr-c307) a specific TLR7  
488 agonist was used to stimulate RAW 264.7 (50 ng/mL) for the indicated amount of time.  
489 Guanosine (Sigmaaldrich, G6264) was used to stimulate RAW 264.7 (200 µM) for the  
490 indicated amount of time. TL8-506, a specific agonist for TLR8, was used to stimulate THP-1  
491 (0.1 µg/mL, 1 µg/mL) for the indicated amount of time. Polyinosinic-polycytidylic acid (Poly(I:C),  
492 Sigmaaldrich, P9582) a synthetic analog of double-stranded RNA (dsRNA) was used to  
493 stimulate HEK293T (50 µg/mL), RAW 264.7 (10 µg/mL), BMDCs (10 µg/mL), and THP-1 (10

494  $\mu\text{g/mL}$ ) for the indicated amount of time. LPS (Sigmaaldrich, L6529) was used to stimulate  
495 RAW 264.7 (0.1  $\mu\text{g/mL}$ ) and THP-1 (0.1  $\mu\text{g/mL}$ ) for the indicated amount of time. Class A CpG  
496 oligonucleotide ODN2216 (InvivoGen, tlr1-2216) was used to stimulate HEK293T (5  $\mu\text{M}$ ) for  
497 the indicated amount of time. Class B CpG oligonucleotide ODN2006 (InvivoGen, tlr1-2006)  
498 was used to stimulate THP-1 (5  $\mu\text{M}$ ) for the indicated amount of time. Class A CpG  
499 oligonucleotide ODN1585 (InvivoGen, tlr1-1585) was used to stimulate BMDCs (0.5  $\mu\text{M}$ , 5  $\mu\text{M}$ )  
500 and RAW 264.7 (0.5  $\mu\text{M}$ , 5  $\mu\text{M}$ ) for the indicated amount of time. Class B CpG oligonucleotide  
501 ODN1668 (InvivoGen, tlr1-1668) was used to stimulate BMDMs (0.5  $\mu\text{M}$ , 5  $\mu\text{M}$ ), BMDCs (0.5  
502  $\mu\text{M}$ , 5  $\mu\text{M}$ ) and RAW 264.7 (0.5  $\mu\text{M}$ , 5  $\mu\text{M}$ ) for the indicated amount of time. Chloroquine (CQ,  
503 Selleck, S6999), an autophagy/lysosome inhibitor, was used to treat RAW 264.7 (50  $\mu\text{M}$ ) for  
504 the indicated amount of time. Enpatoran (M5049, Selleck, S9931) hydrochloride a dual TLR7/8  
505 inhibitor, was used to treat RAW 264.7 (10  $\mu\text{M}$ ) for the indicated amount of time.

506

#### 507 **Expression plasmids and antibodies**

508 Human TLR3, TLR7, TLR8, TLR9 and wild-type UNC93B1 plasmids were constructed by PCR  
509 amplification of UNC93B1 from the cDNAs of the THP-1 cell line, and then cloned into the  
510 pLenti vector or MSCV-puro vectors made in-house, and the mutant plasmids were  
511 constructed by site-directed mutagenesis.

512

513 For western blotting experiments, TLR7 (5632), TLR8 (11886), TLR9 (13674), and GAPDH  
514 (5174) antibodies were purchased from Cell Signaling Technology. Flag (F3165) antibody was  
515 from Sigma aldrich. UNC93B1 (PA5-20510) antibody was from Invitrogen. LAMP1 (ab25630)  
516 antibody was from Abcam.

517

518 For immunofluorescence experiments, TLR7 (5632) and EEA1(3288) antibodies were  
519 purchased from Cell Signaling Technology. LAMP1 (ab25630) antibody was purchased from  
520 Abcam.

521

522 For flow cytometry experiments, V500 Rat Anti-Mouse CD45(30-F11) (561487), BV421

523 Hamster Anti-Mouse CD3e(145-2C11) (562600), FITC Rat Anti-Mouse CD4(RM4-5) (553046),  
524 APC-Cy7 Rat Anti-Mouse CD8a(53-6.7) (557654), APC Rat Anti-Mouse CD19(1D3) (550992),  
525 PE Rat Anti-Mouse CD138(281-2) (553714), BV605 CD317 (BST2) (747606), PE-Cy7 Rat  
526 Anti-Mouse CD45R/B220(RA3-6B2) (552772), BUV496 CD11b (749864), BV750 F4/80  
527 (747295), RB780 Ly-6C (755871), BUV395 I-A, I-E (569244), BUV805 CD44 (741921),  
528 BUV563 CD62L (741230), BV786 Rat Anti-Mouse CD25(PC61) (564023), BV650 Rat Anti-  
529 Mouse IL-17A (TC11-18H10) (564170), BUV737 Rat Anti-Mouse CD21/CD35(7G6) (612810),  
530 RB545 CD23 (756344), BV480 CD95 (746755), BUV615 CD49b (751052), BV711 CD279  
531 (PD-1) (744547), PE-CF594 Rat Anti-Mouse CD185 (CXCR5)(2G8) (562856), and R718 Ly-  
532 6G (567039) antibodies were purchased from BD Biosciences. PE-CYN5 FOXP3 (15-5773-  
533 82), PE-CYN5 FOXP3 (15-5773-82), and PERCPEF710 BCL-6 (46-5453-82) antibodies were  
534 purchased from Invitrogen. Brilliant Violet 570 anti-mouse CD11c (117331) and APC anti-  
535 mouse TNF (506308) antibodies were purchased from Biolegend.

536

### 537 **Dual-luciferase reporter assay**

538 The NF- $\kappa$ B firefly reporter plasmid (pGL4.32 [luc2P/NF- $\kappa$ B-RE/Hygro] and the Renilla  
539 luciferase expression plasmid (pRLCMV-Renilla) were co-transfected along with TLRs and  
540 UNC93B1 expression plasmids into HEK293 cells. After 24 hours of transfection and indicated  
541 treatment, cells were harvested, and luciferase activity was measured using the Dual  
542 Luciferase Reporter Assay Kit (Vazyme, DL101-01). Data were calculated as fold induction by  
543 normalizing firefly luciferase activity to Renilla luciferase activity.

544

### 545 **RNA extraction and quantitative PCR**

546 TRIzol reagent (Invitrogen, 15596026) and RNeasy Mini kit (Qiagen, 74104) were applied to  
547 extract total RNA from cultured cells and murine tissues. One microgram of RNA was reverse-  
548 transcribed using the PrimeScript RT Reagent Kit with gDNA Eraser (Perfect Real Time)  
549 (Takara, RR047A). Gene expression analyses were performed using 2X Universal SYBR  
550 Green Fast qPCR Mix (ABclonal, RK21203) on ROCHE 480II. Relative mRNA expression was  
551 analyzed by the  $\Delta\Delta C_t$  method and normalized to *ACTB* (for human samples) or *Actb* (for

552 mouse samples).

553

### 554 **RNA sequencing**

555 RNA sequencing libraries were generated using the NEBNext Ultra RNA Library Prep Kit for  
556 Illumina (New England Biolabs) following the manufacturer's protocol. The libraries were then  
557 sequenced on an Illumina NovaSeq platform to obtain high-throughput sequencing data. The  
558 resulting reads were mapped to the reference genome, and featureCounts was utilized to  
559 quantify the number of reads mapped to each gene. For differential expression analysis, the  
560 DESeq2 (version 1.44.0) and clusterProfiler (version 4.12.0) R package was employed, which  
561 involved normalization of read counts, statistical testing, and identification of differentially  
562 expressed genes between the experimental conditions. Gene set scores in differential  
563 expression analysis of RNA sequencing data are summing of z-scores of each gene in the  
564 gene set. Z-score of each gene in the gene set is calculated relative to the mean and standard  
565 deviation of Healthy controls. Gene sets from msigDB ([https://www.gsea-](https://www.gsea-msigdb.org/gsea/msigdb)  
566 [msigdb.org/gsea/msigdb](https://www.gsea-msigdb.org/gsea/msigdb)) are used for analysis.

567

### 568 **Single-cell RNA sequencing**

569 For human PBMCs, 8,000-10,000 single cells for each sample were captured and barcoded  
570 with a 10x Genomics Chromium console, while the library of about 10,000 cells from murine  
571 spleen samples were constructed by MGI DNBelab C-TaiM4. The barcoded complementary  
572 DNA was amplified and sequenced by Illumina Novaseq and MGI DNBSEQ-T7 for human  
573 PBMC and murine samples, respectively. Novaseq sequencing data was processed with  
574 cellranger (10X Genomics, version 6.1.1), while DNGSEQ-T7 sequencing data was processed  
575 with DNBC4tools (MGI, version 2.1.1). Downstream quality control, processing and differential  
576 expression analysis were performed by Seurat package (version 4.2.0) and harmony package  
577 (version 1.2.0) in R.

578

### 579 **Flow cytometry analysis**

580 The mice spleen single-cell suspensions were prepared using the plunger end of the syringe

581 and filtered using 100 µm and 40 µm strainers with 2% FBS in PBS. The collected filtrates  
582 were centrifuged at 350 g for 5 min. The cell pellet was suspended in 5 mL RBC lysis buffer,  
583 incubated for 4 min at 25 °C and then mixed with 10 mL of PBS with 2% FBS. The splenocytes  
584 were resuspend in PBS after centrifugation at 350 g for 5 min. Whole blood cells were collected  
585 from heart blood and incubated with 10 mL RBC lysis buffer for 5 min at 25 °C, and then mixed  
586 with 20 mL PBS with 2% FBS. The whole blood cells were resuspended in PBS after  
587 centrifugation at 350 g for 5 min.

588

589 For flow cytometry analysis,  $1 \times 10^6$  cells were incubated with Fixable Viability Stain 440UV (BD  
590 Biosciences, 566332) for 15 min at room temperature protected from light. Washed twice with  
591 fluorescence-activated cell sorting (FACS) buffer (0.5% BSA in PBS) and stained with cell-  
592 surface markers for 1 hours on ice. For fixation and permeabilization, 1.6% PFA and 40%  
593 methanol were used. The cells were then washed twice and stained with intracellular  
594 antibodies for 1 hours on ice. All events were acquired on Cytex Aurora and analyzed by  
595 SpectroFlo and FlowJo\_v.10.8.1. Gating strategy is shown in Supplemental Figure 6.

596

### 597 **ELISA and CBA**

598 Levels of cytokines IL-6, IFN- $\alpha$  and chemokine IP-10 in human serum were determined by  
599 Cytometric Bead Array (BD Bioscience). All data were analyzed by FCAPArray V3 software  
600 (BD Biosciences). Macrophage colony-stimulating factor (M-CSF) (MULTISCIENCES,  
601 EK1144), Granulocyte colony-stimulating factor (G-CSF) (MULTISCIENCES, EK169)  
602 concentrations in human serum were measured by enzyme-linked immunosorbent assay  
603 (ELISA) kit.

604

605 The ELISA kits used for Cxcl1 (EK286), Il-6 (EK206), CRP (EK294) quantification in murine  
606 plasma were purchased from Multisciences. ANA (ml002245), Il-1 $\beta$  (ml098416) and C3  
607 (ml002033) quantification in murine plasma were purchased from Milbio.

608

609 For detecting autoantibodies in murine plasma, coating antigens (1 µg DNA or RNA) were

610 diluted in Coating Buffer and added to an ELISA plate, then incubated overnight at 4 °C. The  
611 plate was blocked with Diluent Buffer for 1 hour at room temperature. Samples and standards  
612 were diluted in Diluent Buffer and incubated for 2 hours at room temperature. Detection  
613 antibodies were added and incubated for 1 hour, followed by HRP conjugate (Beyotime, A0216)  
614 for 30 minutes, both at room temperature. TMB substrate (Beyotime, P0209) was added and  
615 incubated for 30 minutes, then stop solution (Beyotime, P0215) was added. Absorbance was  
616 measured at 450 nm using a microplate reader.

617

### 618 **Western blotting and Immunoprecipitation**

619 Cells were lysed in ice-cold lysis buffer ( 50 mM Tris - HCl, pH 8.0, 150 mM NaCl, 5 mM EDTA,  
620 1% digitonin) supplemented with Complete Mini EDTA-free (4693159001, Roche) and  
621 PhosSTOP (4906837001, Roche). Protein concentration was measured by a BCA protein  
622 assay kit (23225, Thermo Fisher). Immunoblotting was conducted as described previously  
623 with specific antibodies(38, 39).

624

625 For immunoprecipitation, cell lysates were combined with immunomagnetic beads for 4 hours.  
626 Then, immunocomplexes were washed five times using the lysis buffer and subjected to  
627 western blot analysis.

628

629 The proximity-labeling BioID approach, as previously described(40), was used to detect the  
630 interactions between UNC93B1 and TLR7. RAW 264.7 cells stably expressing UNC93B1  
631 (WT)-BirA\* /UNC93B1 (R95L)-BirA\* were incubated for 24 hours in complete media  
632 supplemented with or without 20 µM biotin. After three washes with PBS, cells were lysed in  
633 lysis buffer (50 mM Tris-Cl, 137 mM NaCl, 1 mM EDTA, 1% Triton X-100, 10% Glycerol)  
634 supplemented with Complete Mini EDTA-free (4693159001, Roche). Lysed cells were  
635 centrifuged under 14,000 g for 10 min at 4 °C. Supernatants were then incubated with 20 µL  
636 streptavidin agarose beads for 24 h at 4 °C. Beads were pelleted by centrifugation at 2,000  
637 rpm for 2 min and eluted with Elute Buffer (1.5x SDS protein sample buffer containing 1 mM  
638 biotin) for western blot analysis.

639

## 640 **Immunofluorescence**

641 For immunofluorescence (IF) staining of murine kidney tissue cryosections, the sections were  
642 first fixed and permeabilized, followed by blocking with 10% normal goat serum (NGS,  
643 Beyotime, C0265) in PBS for 1 hour. Mouse antibodies diluted in 10% NGS/PBS (IgG 1:200;  
644 C3 1:200) were applied to the sections and incubated overnight at 4°C. Secondary antibodies  
645 diluted at 1:500 in 10% NGS/PBS were then incubated with the sections at room temperature  
646 for 1 hour.

647

648 For IF staining of cultured cells, cells were plated onto glass coverslips and allowed to settle  
649 overnight. Cells were fixed with methanol for 5 min at -20 °C and permeabilized with 100 µM  
650 digitonin-PBS for 5 min at RT. After washing 3 times with PBS, cells were blocked in 10% NGS  
651 (Beyotime, C0265) in PBS for 30min. Slides were stained in blocking buffer with primary  
652 antibodies overnight at 4 °C. After washing 3 times with PBS, slides were incubated for 1 hour  
653 with secondary antibodies in blocking buffer at RT. After washing 3 times with PBS, slides were  
654 mounted using Mounting Medium with DAPI (ab104139, abcam). Images were acquired and  
655 quantified by ZEISS LSM 900.

656

## 657 **Immunohistochemistry**

658 Freshly dissected murine spleens, kidneys, livers and lungs were fixed in 4%  
659 paraformaldehyde (Sigma-Aldrich, P6148) for 16 hours at 4 °C, embedded with paraffin and  
660 stained with hematoxylin/eosin (H&E) or periodic acid-Schiff (PAS). The tissue slides were  
661 scanned using Aperio ScanScope XT scanner (Leica). Glomerular size was analyzed in a  
662 blinded manner using NDP.view 2. Glomerular size was determined from an area with at least  
663 10 glomeruli per kidney section from at least 3 mice in each group.

664

## 665 **Author contributions**

666 QZ, PT and XY designed the study, directed, and supervised the research. XH, RW, SO, and  
667 QW contributed equally. PT, RW, QW, WD, YZ, OX and HY performed experiments. XH

668 analyzed the data. QZ and SO enrolled the patient, collected, and interpreted clinical  
669 information. QZ, PT, XH, and RW wrote the manuscript, with input from others. All authors  
670 contributed to the review and approval of the manuscript.

671

## 672 **Acknowledgments**

673 We thank the patient and the unaffected controls for their support during this research study.  
674 We thank the core facility of the Life Sciences Institute, Zhejiang University and core facilities  
675 of Zhejiang University Medical Center/Liangzhu laboratory for technical assistance. The works  
676 of QZ were supported by grants 82225022, 32141004 and 32321002 from The National  
677 Natural Science Foundation of China. The works of X.Y. were supported by the Major Program  
678 of the National Natural Science Foundation of China (82394424), the National Natural Science  
679 Foundation of China (82471844), the Hundred-Talent Program of Zhejiang University and  
680 Leading Innovative and Entrepreneur Team Introduction Program of Zhejiang (2021R01012).  
681 The works of PT were supported by grants 82201926 and 82471814 from The National Natural  
682 Science Foundation of China, BX2021259 and 2021M702852 from China Postdoctoral  
683 Science Foundation. The works of RW were supported by grant 82300893 from The National  
684 Natural Science Foundation of China.

685

## 686 **Competing interests**

687 Authors declare that they have no competing interests.

688

## 689 **Statistics**

690 Statistical analyses were performed using GraphPad Prism 8. All values were as mean  $\pm$  SEM  
691 and calculated from the average of at least three independent biological replicates unless  
692 specifically stated. Statistical differences were evaluated using the Student's *t* test (unpaired  
693 and two-tailed ) for comparisons between two groups or ANOVA for comparisons of more than  
694 two groups. In all tests, a 95% confidence interval was used, for which  $P < 0.05$  was  
695 considered a significant difference. *P* values obtained in next-generation sequencing were  
696 adjusted by FDR using R Software (R version 4.4.1).



697

## 698 **Study approval**

699 This study involves human participants and was approved by the institutional review boards  
700 of the Children's Hospital of Zhejiang University School of Medicine in China. Participants  
701 provided written informed consent to participate in the study before taking part.

702 Mice were bred and maintained in specific-pathogen-free conditions at the Laboratory Animal  
703 Center of Zhejiang University, with normal diet, 12 h light/dark cycle, 20-26 °C and humidity of  
704 40-70%. Experimentation was approved by the Institutional Animal Care and Use Committee  
705 of Zhejiang University.

706

## 707 **Data and materials availability**

708 All data are available in the main text or the Supplemental materials.

709


## 710 **References**

- 711 1. Omarjee O, et al. Monogenic lupus: Dissecting heterogeneity. *Autoimmun Rev.*  
712 2019;18(10):102361.
- 713 2. Demirkaya E, et al. New Horizons in the Genetic Etiology of Systemic Lupus Erythematosus and  
714 Lupus-Like Disease: Monogenic Lupus and Beyond. *J Clin Med.* 2020;9(3).
- 715 3. O'Neill LA, and Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor  
716 signalling. *Nat Rev Immunol.* 2007;7(5):353-64.
- 717 4. Fitzgerald KA, and Kagan JC. Toll-like Receptors and the Control of Immunity. *Cell.*  
718 2020;180(6):1044-66.
- 719 5. Gantier MP, et al. TLR7 is involved in sequence-specific sensing of single-stranded RNAs in human  
720 macrophages. *J Immunol.* 2008;180(4):2117-24.
- 721 6. Hornung V, et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of  
722 human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. *J*  
723 *Immunol.* 2002;168(9):4531-7.
- 724 7. van der Made CI, et al. Presence of Genetic Variants Among Young Men With Severe COVID-19.  
725 *Jama.* 2020;324(7):663-73.
- 726 8. Brown GJ, et al. TLR7 gain-of-function genetic variation causes human lupus. *Nature.*  
727 2022;605(7909):349-56.
- 728 9. David C, et al. Interface Gain-of-Function Mutations in TLR7 Cause Systemic and Neuro-  
729 inflammatory Disease. *J Clin Immunol.* 2024;44(2):60.
- 730 10. Stremenova Spigarova J, et al. A de novo TLR7 gain-of-function mutation causing severe  
731 monogenic lupus in an infant. *J Clin Invest.* 2024;134(13).
- 732 11. Cervantes JL, et al. TLR8: the forgotten relative revindicated. *Cell Mol Immunol.* 2012;9(6):434-8.
- 733 12. Aluri J, et al. Immunodeficiency and bone marrow failure with mosaic and germline TLR8 gain of

- 734 function. *Blood*. 2021;137(18):2450-62.
- 735 13. Tabeta K, et al. The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling  
736 via Toll-like receptors 3, 7 and 9. *Nat Immunol*. 2006;7(2):156-64.
- 737 14. Itoh H, et al. UNC93B1 physically associates with human TLR8 and regulates TLR8-mediated  
738 signaling. *PLoS One*. 2011;6(12):e28500.
- 739 15. Kim YM, et al. UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes. *Nature*.  
740 2008;452(7184):234-8.
- 741 16. Casrouge A, et al. Herpes simplex virus encephalitis in human UNC-93B deficiency. *Science*.  
742 2006;314(5797):308-12.
- 743 17. Ishida H, et al. Cryo-EM structures of Toll-like receptors in complex with UNC93B1. *Nat Struct Mol*  
744 *Biol*. 2021;28(2):173-80.
- 745 18. Aringer M, et al. 2019 European League Against Rheumatism/American College of Rheumatology  
746 Classification Criteria for Systemic Lupus Erythematosus. *Arthritis Rheumatol*. 2019;71(9):1400-12.
- 747 19. Postal M, et al. Type I interferon in the pathogenesis of systemic lupus erythematosus. *Curr Opin*  
748 *Immunol*. 2020;67:87-94.
- 749 20. Reizis B. Plasmacytoid Dendritic Cells: Development, Regulation, and Function. *Immunity*.  
750 2019;50(1):37-50.
- 751 21. Granot T, et al. Dendritic Cells Display Subset and Tissue-Specific Maturation Dynamics over  
752 Human Life. *Immunity*. 2017;46(3):504-15.
- 753 22. Shin KS, et al. Monocyte-Derived Dendritic Cells Dictate the Memory Differentiation of CD8(+) T  
754 Cells During Acute Infection. *Front Immunol*. 2019;10:1887.
- 755 23. Rael VE, et al. Large-scale mutational analysis identifies UNC93B1 variants that drive TLR-mediated  
756 autoimmunity in mice and humans. *J Exp Med*. 2024;221(8).
- 757 24. David C, et al. Gain-of-function human UNC93B1 variants cause systemic lupus erythematosus  
758 and chilblain lupus. *J Exp Med*. 2024;221(8).
- 759 25. Al-Azab M, et al. Genetic variants in UNC93B1 predispose to childhood-onset systemic lupus  
760 erythematosus. *Nat Immunol*. 2024;25(6):969-80.
- 761 26. Mishra H, et al. Disrupted degradative sorting of TLR7 is associated with human lupus. *Sci Immunol*.  
762 2024;9(92):eadi9575.
- 763 27. Wolf C, et al. UNC93B1 variants underlie TLR7-dependent autoimmunity. *Sci Immunol*.  
764 2024;9(92):eadi9769.
- 765 28. Rodero MP, et al. Type I interferon-mediated autoinflammation due to DNase II deficiency. *Nat*  
766 *Commun*. 2017;8(1):2176.
- 767 29. Al-Mayouf SM, et al. Loss-of-function variant in DNASE1L3 causes a familial form of systemic  
768 lupus erythematosus. *Nat Genet*. 2011;43(12):1186-8.
- 769 30. Crow YJ, et al. Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 cause Aicardi-  
770 Goutières syndrome at the AGS1 locus. *Nat Genet*. 2006;38(8):917-20.
- 771 31. Peng J, et al. Clinical Implications of a New DDX58 Pathogenic Variant That Causes Lupus Nephritis  
772 due to RIG-I Hyperactivation. *J Am Soc Nephrol*. 2023;34(2):258-72.
- 773 32. Fukui R, et al. Unc93B1 restricts systemic lethal inflammation by orchestrating Toll-like receptor 7  
774 and 9 trafficking. *Immunity*. 2011;35(1):69-81.
- 775 33. Majer O, et al. UNC93B1 recruits syntenin-1 to dampen TLR7 signalling and prevent autoimmunity.  
776 *Nature*. 2019;575(7782):366-70.
- 777 34. Majer O, et al. Release from UNC93B1 reinforces the compartmentalized activation of select TLRs.

- 778 *Nature*. 2019;575(7782):371-4.
- 779 35. Tanji H, et al. Structural reorganization of the Toll-like receptor 8 dimer induced by agonistic  
780 ligands. *Science*. 2013;339(6126):1426-9.
- 781 36. Zhou Q, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. *N Engl J*  
782 *Med*. 2014;370(10):911-20.
- 783 37. Zhou Q, et al. Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an  
784 early-onset autoinflammatory disease. *Nat Genet*. 2016;48(1):67-73.
- 785 38. Tao P, et al. A dominant autoinflammatory disease caused by non-cleavable variants of RIPK1.  
786 *Nature*. 2020;577(7788):109-14.
- 787 39. Wang Y, et al. Identification of an IL-1 receptor mutation driving autoinflammation directs IL-1-  
788 targeted drug design. *Immunity*. 2023;56(7):1485-501.e7.
- 789 40. Roux KJ, et al. A promiscuous biotin ligase fusion protein identifies proximal and interacting  
790 proteins in mammalian cells. *J Cell Biol*. 2012;196(6):801-10.
- 791
- 792

793 **Figures**



794

795 **Figure 1. Inflammatory signaling activated in an early-onset SLE patient with *UNC93B1***

796 **R95L mutation.**

797 (A) Clinical images displaying skin rashes on the patient's back (left) and hip (right).

798 (B) Pedigree of the patient with a homozygous variant c.284G>T (NM\_030930), p.R95L in  
799 *UNC93B1*.

800 (C) Validation of the homozygous variant in *UNC93B1* using Sanger sequencing.

801 (D) The evolutionary conservation of the arginine at position 95 in *UNC93B1* across species.

802 (E) Serum Levels of cytokines IL-6, IFN- $\alpha$ , and chemokine IP-10 in the patient (P) and healthy  
803 controls (HCs, n = 6) were detected by CBA.

804 (F) Serum Levels of colony-stimulating factors M-CSF and G-CSF in the patient (P) and  
805 healthy controls (HCs, n = 6) were detected by ELISA.

806 (G) Transcription level of NF- $\kappa$ B and type I IFN pathways in PBMCs from the patient (P) and  
807 healthy controls (HC, n = 3). Analysis of each sample was performed in duplicate.

808 (H) qPCR analysis of NF- $\kappa$ B and type I IFN pathways related genes in PBMCs from the patient  
809 (P) compared with healthy controls (HCs, n = 5).


810 (I) Uniform manifold approximation and projection (UMAP) visualization and marker-based  
811 annotation of 18 cell subtypes from the patient and healthy controls (HCs, n = 3).

812 (J) UMAP visualization of the target pathway scoring in the patient and healthy controls (HCs,  
813 n = 3). Upper, pathway scoring based on genes on NF- $\kappa$ B signal transduction gene set in  
814 Gene Ontology database; bottom, pathway scoring based on genes on response to type I IFN  
815 gene set in Gene Ontology database. Scores were generated based on Seurat  
816 Addmodulescore method.

817 (K) Expression levels of essential genes in NF- $\kappa$ B and type I IFN pathways in various immune  
818 cells among the patient and healthy controls (HCs, n = 3).

819 (L) Enrichment of upregulated pathways of differential expressed gene in patient's DCs based  
820 on GSEA.

821




822

823 **Figure 2. *UNC93B1*<sup>R95L</sup> mutation promotes inflammation through TLR7/TLR8 activation.**

824 (A) NF-κB luciferase assays in HEK293T cells co-transfected TLR7 (left) or TLR8 (right) with

825 different UNC93B1 expression plasmids, treated as indicated (n = 3 biological replicates).  
826 Data represent mean  $\pm$  SEM; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ ; two-tailed unpaired Student's *t* test.  
827 EV: empty vector; WT: wild-type UNC93B1; R95L: R95L mutant; HR: H412R mutant.  
828 (B) qPCR analysis of *IL8* transcription level in HEK293T cells co-transfected TLR7 (left) or  
829 TLR8 (right) with different UNC93B1 expression plasmids, treated as indicated (n = 3  
830 biological replicates). Data represent mean  $\pm$  SEM; \*\*\*,  $P < 0.001$ ; two-tailed unpaired  
831 Student's *t* test.  
832 (C) qPCR analysis of *IL8* in HEK293T cells co-transfected TLR3 with different UNC93B1  
833 expression plasmids, treated as indicated (n = 3 biological replicates). Data represent mean  
834  $\pm$  SEM; two-tailed unpaired Student's *t* test. EV: empty vector; WT: wild-type UNC93B1; R95L:  
835 R95L mutant; HR: H412R mutant.  
836 (D) NF- $\kappa$ B luciferase assay in HEK293T cells co-transfected TLR9 with different UNC93B1  
837 expression plasmids, treated as indicated (n = 3 biological replicates). Data represent mean  
838  $\pm$  SEM; \*,  $P < 0.05$ ; two-tailed unpaired Student's *t* test. WT: wild-type UNC93B1; R95L: R95L  
839 mutant.  
840 (E) qPCR analysis of *IL1B*, *IL6*, *IL8* and *TNF* transcription levels in THP-1 expressing the WT  
841 or R95L mutant UNC93B1 treated with various TLRs agonists (n = 3 biological replicates).  
842 Data represent mean  $\pm$  SEM; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ ; two-tailed unpaired Student's *t* test.  
843 (F, G) Intracellular cytokine staining of Tnf in mouse RAW 264.7 expressing the WT or R95L  
844 mutant UNC93B1, and treated with various TLRs agonists or inhibitors.  
845 (H, I) qPCR analysis of NF- $\kappa$ B (H) and type I IFN (I) pathways related genes transcription in  
846 BMDCs from indicated mice treated with various TLRs agonists(n = 5 mice per group). Data  
847 represent mean  $\pm$  SEM; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ ; two-tailed unpaired Student's *t* test.  
848



849

850 **Figure 3. Mice with *Unc93b1*<sup>R95L</sup> mutation develop systemic inflammation and**  
 851 **autoimmune pathology.**

852 (A) Sanger sequencing showing the amino acid substitution *Unc93b1*,  
 853 ENSMUST00000162708.7: c.283\_285delinsCTC, p.R95L in homozygous knock-in mice. Wild  
 854 type (+/+), heterozygous (+/R95L), and homozygous (R95L/R95L) are indicated.



855 (B) Body weight of *Unc93b1*<sup>+/+</sup>, *Unc93b1*<sup>+/R95L</sup> and *Unc93b1*<sup>R95L/R95L</sup> mice.

856 (C) Representative images of splenomegaly and normalized spleen weight to body weight  
857 (spleen index) of 12-wk-old mice (n = 5 per group). Data represent mean ± SEM; \*\*, *P* < 0.01;  
858 \*\*\*, *P* < 0.001; one-way ANOVA.

859 (D) Plasma levels of anti-DNA, anti-RNA, ANA, CRP and C3 in the indicated mice were  
860 detected using ELISA (n = 5 per group). Data represent mean ± SEM; \*, *P* < 0.05; \*\*, *P* < 0.01;  
861 \*\*\*, *P* < 0.001; one-way ANOVA.

862 (E) Plasma levels of Il-1β, Il-6 and chemokine Cxcl1 in the indicated mice were detected using  
863 ELISA (*Unc93b1*<sup>+/+</sup>, n = 10; *Unc93b1*<sup>+/R95L</sup>, n = 6; *Unc93b1*<sup>R95L/R95L</sup>, n = 6). Data represent mean  
864 ± SEM; \*\*, *P* < 0.01; \*\*\*, *P* < 0.001; one-way ANOVA.

865 (F) H&E staining of the spleen from indicated mice (left). Normalized white pulp was calculated  
866 (right). (*Unc93b1*<sup>+/+</sup>, n = 10; *Unc93b1*<sup>+/R95L</sup>, n = 6; *Unc93b1*<sup>R95L/R95L</sup>, n = 6). Data represent  
867 mean ± SEM; \*, *P* < 0.05; \*\*\*, *P* < 0.001; one-way ANOVA.

868 (G) PAS staining of the kidney from indicated mice (left). Glomerulus area was calculated  
869 (right). (*Unc93b1*<sup>+/+</sup>, n = 10; *Unc93b1*<sup>+/R95L</sup>, n = 6; *Unc93b1*<sup>R95L/R95L</sup>, n = 6).Data represent  
870 mean ± SEM; \*\*\*, *P* < 0.001; one-way ANOVA.


871 (H) PAS staining of the lung and liver from indicated mice.

872 (I) Short fasting blood glucose levels of the indicated mice (n = 8 per group). Data represent  
873 mean ± SEM; \*\*, *P* < 0.01; two-tailed unpaired Student's *t* test.

874 (J) Top 15 enriched pathways of differential expressed genes in murine hepatocytes from the  
875 *Unc93b1*<sup>+/+</sup>, and *Unc93b1*<sup>R95L/R95L</sup> mice.

876 (K) Representative immunofluorescent images of IgG and C3 in glomerulus from the indicated  
877 mice(left). IgG (top) and C3 (bottom) staining in individual glomerulus was quantified (n = 30  
878 glomerulus from three mice per group). Data represent mean ± SEM; \*\*\*, *P* < 0.001; one-way  
879 ANOVA.

880 (L) qPCR analysis of NF-κB and type I IFN pathways related genes in the spleen, kidney, liver,  
881 and brain from the indicated mice (spleen, kidney and liver, n = 8-10 per group; brain, n = 4-7  
882 per group). Data represent mean ± SEM; \*\*, *P* < 0.01; \*\*\*, *P* < 0.001; one-way ANOVA.  
883



884

885 **Figure 4. Effects of *UNC93B1*<sup>R95L</sup> mutation on immune cell populations in mice.**

886 (A) UMAP visualization and marker-based annotation of 28 cell subtypes from splenocytes of  
 887 *Unc93b1*<sup>R95L/R95L</sup> and *Unc93b1*<sup>+/+</sup> mice (n = 3 mice per group). NKT, natural killer T cell; gdT,  
 888 gamma-delta T cell; Treg, regulatory T cell; MZ B, marginal zone B cell; Fo B, follicular B cell;  
 889 DC, dendritic cell; MDP, myeloid dendritic progenitor.

890 (B) Upregulated inflammatory signal in *Unc93b1*<sup>R95L/R95L</sup> mice. Left, pathway scoring of NF- $\kappa$ B  
 891 signal transduction gene set in Gene Ontology database; right, GSEA plot shows upregulated

892 TNF signaling pathway in murine splenic T cells. Pathway score is calculated by the Seurat  
893 Addmodulescore method.

894 (C) Upregulated autoimmune characteristics in *Unc93b1<sup>R95L/R95L</sup>* mice. Left, pathway scoring  
895 of immunoglobulin production gene set in Gene Ontology database; right, GSEA plot shows  
896 upregulated SLE signaling pathway in murine splenic B cells. Pathway score is calculated by  
897 the Seurat Addmodulescore method.


898 (D-G) Splenic germinal center B cells (GC B) (D), age-associated B cells (ABC) (E), marginal  
899 zone B cells (MZ B) (F), follicular B cells (F), and plasma cells (G) distribution are indicated by  
900 FACS plots and percentages (n = 11 mice per group). Data represent mean  $\pm$  SEM; \*\*\*,  $P <$   
901 0.001; two-tailed unpaired Student's *t* test.

902 (H, I) Splenic CD4<sup>+</sup> T cells (H) and CD8<sup>+</sup> T cells (I) activation are indicated by FACS plots and  
903 percentages (n = 8 mice per group). Data represent mean  $\pm$  SEM; \*\*,  $P <$  0.01; \*\*\*,  $P <$  0.001;  
904 two-tailed unpaired Student's *t* test.

905 (J) Flow cytometric analysis of splenic T cell populations from indicated mice (n = 6-8 mice per  
906 group). Data represent mean  $\pm$  SEM; \*\*,  $P <$  0.01; \*\*\*,  $P <$  0.001; two-tailed unpaired Student's  
907 *t* test.

908 (K) Flow cytometric analysis of splenic NK, pDCs, mDCs and monocytes populations from  
909 indicated mice (NK, n = 6-7 mice per group; pDCs, mDCs and monocytes, n = 11 mice per  
910 group). Data represent mean  $\pm$  SEM; \*,  $P <$  0.05; \*\*,  $P <$  0.01; \*\*\*,  $P <$  0.001; two-tailed  
911 unpaired Student's *t* test.

912



913  
914 **Figure 5. UNC93B1 R95L mutation enhances TLR7 ligand binding by weakening their**  
915 **interaction.**

916 (A) The structure of TLR7 and UNC93B1 complex (PDB: 7CYN) shows H1 helix (residues 91-  
917 97) of UNC93B1 directly contacting two loop regions of the C-terminal LRR-CT domain of  
918 TLR7. Protein structural analysis was executed with Pymol.

919 (B) Flag-immunoprecipitation and western blot analyses of UNC93B1 and TLR7 (left)/TLR8  
920 (right) interaction in HEK293T cells.

921 (C) TLR8-immunoprecipitation and western blot analyses of UNC93B1 and TLR8 interaction  
922 in HEK293T cells.


923 (D) BioID and western blot analyses of UNC93B1 and TLR7 interaction in RAW 264.7  
924 cells.

925 (E) Immunoblots of TLR7 in endosomes and late endosomes/lysosomes from RAW 264.7  
926 cells expressing the WT or R95L mutant UNC93B1.

927 (F, G) Representative immunofluorescent images (F) and quantification of the colocalization  
928 between Tlr7 and Lamp1 or Eea1 in BMDMs from the indicated mice (G) (n = 14-18 cells per  
929 group). Data represent mean ± SEM; two-tailed unpaired Student's *t* test.

930 (H) RNA pull-down and western blot analyses of ssRNA binding affinity of Tlr7 in BMDCs.

931 (I) Graphic model of how R95L mutation affect UNC93B1/TLR axis and downstream signaling.



932

933 **Supplemental Figure 1. Inflammatory signaling activated in the patient with UNC93B1**  
 934 **R95L mutation.**

935 (A) Comparison of gene set score of inflammatory response genes in msigDB and NF-κB and  
 936 type I IFN response genes between patient and healthy controls (HCs, n = 3).


937 (B) Top 15 enrichment of upregulated pathways of differential expressed gene in patient based  
 938 on GSEA.

939 (C) Marker genes used for cluster annotation in human PBMCs single-cell RNA sequencing.


940 (D) Top 15 enrichment of upregulated pathways of differential expressed gene in patient's T  
 941 cells based on GSEA.

942

A



B



943


944 **Supplemental Figure 2. UNC93B1 R95L mutation promotes inflammation through**  
 945 **TLR7/TLR8 activation.**

946 (A) qPCR analysis of NF- $\kappa$ B and type I IFN pathways related genes transcription in RAW 264.7  
 947 cells treated with various TLRs agonists (n = 3 biological replicates). Data represent mean  $\pm$   
 948 SEM; \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ ; two-tailed unpaired Student's  $t$  test.

949 (B) qPCR analysis of NF- $\kappa$ B and type I IFN pathways related genes transcription in BMDMs  
 950 from indicated mice treated with various TLRs agonists (n = 3-5 mice per group). Data  
 951 represent mean  $\pm$  SEM; \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ ; two-tailed unpaired Student's

952  $t$  test.

953




954

955 **Supplemental Figure 3. Mice with *Unc93b1<sup>R95L</sup>* mutation develop systemic inflammation**  
 956 **and autoimmune pathology.**

957 (A) Normalized kidney, liver, lung weight to body weight of 12-wk-old mice (female, n = 4 per



958 group; male, n = 5 per group). Data represent mean  $\pm$  SEM; \*\*,  $P < 0.01$ ; one-way ANOVA.  
959 (B) PAS staining of the kidney from indicated mice.  
960 (C) Comparison of gene set score of NF- $\kappa$ B and type I IFN response genes and GSEA in TNF  
961 signaling pathway of liver and spleen tissues from the *Unc93b1*<sup>+/+</sup> and *Unc93b1*<sup>R95L/R95L</sup> mice.  
962 NES, normalized enrichment score.  
963 (D) Top 15 enrichment of upregulated pathways of differential expressed gene between the  
964 *Unc93b1*<sup>+/+</sup> and *Unc93b1*<sup>R95L/R95L</sup> mice based on GSEA. NES, normalized enrichment score.  
965 (E) qPCR analysis of NF- $\kappa$ B and type I IFN pathways related genes in the spleen, kidney, liver,  
966 brain, lung and quadricep from the indicated mice (spleen, kidney and liver, n = 8-10 per group;  
967 brain, lung and quadricep, n = 4-7 per group). Data represent mean  $\pm$  SEM; \*,  $P < 0.05$ ; \*\*,  $P$   
968  $< 0.01$ ; \*\*\*,  $P < 0.001$ ; one-way ANOVA.  
969



970


971 **Supplemental Figure 4. Single-cell sequencing analysis of murine splenocytes.**

972 (A) Marker genes used for cluster annotation in murine splenocytes single-cell RNA  
973 sequencing.

974 (B) Cell ratio of different cell clusters among murine splenocytes based on single-cell  
975 sequencing from the *Unc93b1*<sup>+/+</sup> and *Unc93b1*<sup>R95L/R95L</sup> mice.

976 NKT, natural killer T cell; gdT, gamma-delta T cell; Treg, regulatory T cell; MZ B, marginal zone  
977 B cell; Fo B, follicular B cell; DC, dendritic cell; MDP, myeloid dendritic progenitor.

978



979

980 **Supplemental Figure 5. Effects of *Unc93b1*<sup>R95L</sup> mutation on immune cell populations in**  
 981 **mice.**

982 (A-C) germinal center B cells (GC B) (A), age-associated B cells (ABC) (B), marginal zone B  
 983 cells (MZ B) and follicular B cells (C) distribution in peripheral blood of *Unc93b1*<sup>R95L/R95L</sup> and  
 984 *Unc93b1*<sup>+/+</sup> mice are indicated by FACS plots and percentages (n = 7 mice per group). Data  
 985 represent mean ± SEM; \*\*, P < 0.01; \*\*\*, P < 0.001; two-tailed unpaired Student's t test.

986 (D, E) Peripheral blood CD4<sup>+</sup> T cells (D) and CD8<sup>+</sup> T cells (E) activation are indicated by FACS  
 987 plots and percentages (n = 7 mice per group). Data represent mean ± SEM; \*\*\*, P < 0.001;  
 988 two-tailed unpaired Student's t test.

989 (F) Flow cytometric analysis of peripheral blood T cell populations from indicated mice (n = 7  
 990 mice per group). Data represent mean ± SEM; \*\*, P < 0.01; \*\*\*, P < 0.001; two-tailed unpaired


991 Student's *t* test.

992 (G) Flow cytometric analysis of peripheral blood pDCs, mDCs and monocytes populations  
993 from indicated mice (n = 7 mice per group). Data represent mean ± SEM; \*, *P* < 0.05; \*\*, *P* <  
994 0.01; two-tailed unpaired Student's *t* test.

995 (H) Cell communication of MHC-II signaling in splenocytes from the *Unc93b1*<sup>+/+</sup> and  
996 *Unc93b1*<sup>R95L/R95L</sup> mice. NKT, natural killer T cell; gdT, gamma-delta T cell; Treg, regulatory T  
997 cell; MZ B, marginal zone B cell; Fo B, follicular B cell; DC, dendritic cell; MDP, myeloid  
998 dendritic progenitor.

999 (I) Signaling received by T cells from DCs in splenocytes from the *Unc93b1*<sup>+/+</sup> and  
1000 *Unc93b1*<sup>R95L/R95L</sup> mice.

1001



### Supplemental Figure 6. Gating strategies.

Representative gating strategies for germinal center B cells (GC B), age-associated B cells (ABC), marginal zone B cells (MZ B), and follicular B cells, plasma cells, CD4+ T cells, CD8+ T cells, NKT, DNT, Treg, Tfh, eTh, Th17, NK, pDCs, mDCs and monocytes in spleen or peripheral blood. These strategies used for data presented in Figure 4 and Supplemental Figure 5.